Atlas Trials

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Clinical trial NCT05800366 · RECRUITING

Trial details

NCT number
NCT05800366
Sponsor
Jennifer Crombie, MD
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
LymphomaLymphoma, Large B-Cell, Diffuse
Start date
2023-04-06
Primary completion
2026-09-15
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.